	DepoMed Urges Shareholders to Reject Horizon Offer - WSJ
	Depomed: The Next Big Specialty Pharma Success Story - Yahoo Finance
	Depomed Gets Favorable Nucynta Patent Decision - WSJ
	Horizon's Hostile Bid for DepoMed Is Too Low - Fox Business
	How Much Could DepoMed Fetch in a Deal? - Fox Business
	Depomed Unfairly Slammed for Serada Phase III Results
	DepoMed (DEPO) Stock Spikes After Receiving Unsolicited $3 Billion Bid From Horizon Pharma - TheStreet
	Depomed Will Engage in Mediation to Resolve Dispute With Abbott; Comments on DM-1796 Regulatory Status and Orphan Drug Designation - NBC News